IQVIA Holdings Inc. (NYSE:IQV) Receives $229.13 Consensus Price Target from Analysts

Shares of IQVIA Holdings Inc. (NYSE:IQV) have earned a consensus rating of “Buy” from the seventeen ratings firms that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $229.1250.

A number of analysts have recently issued reports on the company. Jefferies Financial Group decreased their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 6th. BMO Capital Markets set a $250.00 price target on shares of IQVIA in a research report on Friday, February 6th. Citigroup decreased their price objective on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research note on Friday, February 6th. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a research note on Thursday, January 22nd. Finally, Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, February 21st.

IQVIA Trading Up 0.1%

Shares of IQV opened at $164.08 on Friday. IQVIA has a twelve month low of $134.65 and a twelve month high of $247.04. The firm has a market capitalization of $27.84 billion, a P/E ratio of 20.88, a price-to-earnings-growth ratio of 1.58 and a beta of 1.39. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09. The stock’s fifty day simple moving average is $186.70 and its 200 day simple moving average is $205.47.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.40 by $0.02. The company had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, equities research analysts forecast that IQVIA will post 10.84 earnings per share for the current year.

Institutional Investors Weigh In On IQVIA

Institutional investors and hedge funds have recently modified their holdings of the stock. Boston Partners acquired a new position in shares of IQVIA in the 3rd quarter valued at approximately $676,698,000. Norges Bank bought a new stake in shares of IQVIA in the fourth quarter worth $497,445,000. Victory Capital Management Inc. raised its holdings in IQVIA by 2,628.1% in the fourth quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock valued at $377,670,000 after acquiring an additional 1,614,063 shares in the last quarter. Orbis Allan Gray Ltd raised its holdings in IQVIA by 96.5% in the fourth quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company’s stock valued at $428,525,000 after acquiring an additional 933,554 shares in the last quarter. Finally, AQR Capital Management LLC boosted its stake in IQVIA by 130.2% during the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after acquiring an additional 879,701 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.